GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Cyclically Adjusted FCF per Share

Xbrane Biopharma AB (STU:7XB) Cyclically Adjusted FCF per Share : €-0.14 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.031. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.14 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-26), Xbrane Biopharma AB's current stock price is €0.0168. Xbrane Biopharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-0.14. Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF of today is .


Xbrane Biopharma AB Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Cyclically Adjusted FCF per Share Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.14

Competitive Comparison of Xbrane Biopharma AB's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted Price-to-FCF falls into.



Xbrane Biopharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.031/132.2054*132.2054
=-0.031

Current CPI (Mar. 2024) = 132.2054.

Xbrane Biopharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 100.541 0.000
201409 0.000 100.161 0.000
201412 -0.008 100.225 -0.011
201503 -0.046 99.950 -0.061
201506 -0.077 99.995 -0.102
201509 -0.005 100.228 -0.007
201512 -0.047 100.276 -0.062
201603 -0.047 100.751 -0.062
201606 -0.028 101.019 -0.037
201609 -0.024 101.138 -0.031
201612 -0.030 102.022 -0.039
201703 -0.022 102.022 -0.029
201706 -0.016 102.752 -0.021
201709 -0.016 103.279 -0.020
201712 -0.029 103.793 -0.037
201803 -0.016 103.962 -0.020
201806 -0.032 104.875 -0.040
201809 0.052 105.679 0.065
201812 0.062 105.912 0.077
201903 -0.090 105.886 -0.112
201906 -0.023 106.742 -0.028
201909 -0.062 107.214 -0.076
201912 0.004 107.766 0.005
202003 -0.056 106.563 -0.069
202006 0.010 107.498 0.012
202009 -0.060 107.635 -0.074
202012 -0.036 108.296 -0.044
202103 0.000 108.360 0.000
202106 -0.056 108.928 -0.068
202109 -0.045 110.338 -0.054
202112 -0.038 112.486 -0.045
202203 0.006 114.825 0.007
202206 -0.024 118.384 -0.027
202209 -0.036 122.296 -0.039
202212 -0.048 126.365 -0.050
202303 -0.235 127.042 -0.245
202306 -0.050 129.407 -0.051
202309 -0.041 130.224 -0.042
202312 -0.028 131.912 -0.028
202403 -0.031 132.205 -0.031

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Xbrane Biopharma AB  (STU:7XB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xbrane Biopharma AB Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Industry
Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines